India News: Discover the reasons why pharma MNCs like Novartis, AstraZeneca, Pfizer, Sanofi, and GSK are reducing their footprint in India. Learn about the challenges they face, the transition from manufacturing to licensing and marketing agreements, and the impact on the Indian pharma industry.
In a recent meeting held by the drug controller on global clinical trials, the OPPI sought from the government a notification system through the drug regulatory authority s digital portal-SUGAM. It has asked for linking of the SUGAM Portal at Centre and state levels and, then, making public the non-commercial information in respect of the filed/pending applications and the approvals granted, it said.
In their latest report, analysts at IIFL Securities compare the India formulations business of pharma companies, across 14 different parameters, including market share (MS) gains in the domestic pharma market, contribution of volume growth to overall India business growth, among others.